McKinley Capital Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

McKinley Capital Management’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-425	Closed	-$21K	–	291
2019 Q1	$21K	Hold	425	–	–	﹤0.01%	270
2018 Q4	$17K	Sell	425 -427	-50%	-$22K	﹤0.01%	282
2018 Q3	$59K	Sell	852 -73	-8%	-$5.53K	﹤0.01%	278
2018 Q2	$70K	Sell	925 -73	-7%	-$4.59K	﹤0.01%	286
2018 Q1	$52K	Sell	998 -29,291	-97%	-$1.7M	﹤0.01%	301
2017 Q4	$1.62M	Buy	30,289 +56	+0.2%	+$3.12K	0.08%	177
2017 Q3	$1.8M	Buy	30,233 +12,768	+73%	+$772K	0.07%	171
2017 Q2	$1.38M	Buy	+17,465	New	+$1.43M	0.05%	199

Other funds holding EGRX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

HEC

Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

McKinley Capital Management's EGRX Position: Q2 2019 in Review

McKinley Capital Management sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q2 2019, closing a stake of 425 shares — an estimated $21K sold.

McKinley Capital Management first reported a position in EGRX in Q2 2017 and held it in 8 quarters. The position peaked at $1.8M in Q3 2017. 180 funds tracked by Wall St. Rank hold EGRX as of Q2 2019.

McKinley Capital Management reported no remaining Eagle Pharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
McKinley Capital Management sold 425 Eagle Pharmaceuticals, Inc. shares in Q2 2019, an estimated $21K.
McKinley Capital Management first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2017 and held it in 8 quarters.
McKinley Capital Management's Eagle Pharmaceuticals, Inc. position peaked at $1.8M in Q3 2017.
180 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2019.

Based on McKinley Capital Management's 13F filing for Q2 2019, filed 7 Aug 2019.